Biofermin Pharmaceutical Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biofermin Pharmaceutical Company Limited with three other
pharmaceutical manufacturers in Asia:
Astrazeneca Pharma India Ltd
sales of 5.64 billion Indian Rupees [US$84.50 million]
of which 98%
Sequent Scientific Limited
(6.34 billion Indian Rupees [US$95.11 million]
of which 99%
was Pharmaceuticals), and
Ind-Swift Laboratories Limited
based in India
(6.53 billion Indian Rupees [US$97.92 million]
Biofermin Pharmaceutical Company Limited reported sales of ¥9.67 billion (US$92.80 million)
March of 2016.
decrease of 10.9%
versus 2015, when the company's sales were ¥10.85 billion.
The sales level in 2016 was fairly close to the level five years ago: in 2011, Biofermin Pharmaceutical Company Limited had sales
of ¥9.07 billion.
Contributing to the drop in overall sales was the 30.0% decline
in Biofermin Synthetic Drugs, from ¥1.14 billion to ¥796.78 million.
There were also decreases in sales in
New Biofermins (down 7.3% to ¥5.96 billion)
Biofermin Tablet (down 6.6% to ¥1.58 billion)
Bioferminr (down 27.3% to ¥673.73 million)
Other (down 0.7% to ¥657.40 million)